Les cancers héréditaires du sein vus par le pathologiste

Melchor, 2013, The complex genetic landscape of familial breast cancer, Hum Genet, 132, 845, 10.1007/s00439-013-1299-y Lord, 2017, PARP inhibitors: synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344 Dedes, 2011, Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations, Cell Cycle, 10, 1192, 10.4161/cc.10.8.15273 Easton, 2015, Gene-panel sequencing and the prediction of breast-cancer risk, N Engl J Med, 72, 2243, 10.1056/NEJMsr1501341 Futreal, 1994, BRCA1 mutations in primary breast and ovarian carcinomas, Science, 266, 120, 10.1126/science.7939630 Lakhani, 1999, The pathology of hereditary breast cancer, Dis Markers, 15, 113, 10.1155/1999/459486 Curtit, 2015, First description of a sporadic breast cancer in a woman with BRCA1 germline mutation, Oncotarget, 6, 35616, 10.18632/oncotarget.5348 Nones, 2019, Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers, Ann Oncol, 30, 1071, 10.1093/annonc/mdz132 Lakhani, 2005, Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype, Clin Cancer Res, 11, 5175, 10.1158/1078-0432.CCR-04-2424 Freneaux, 2000, Low expression of bcl-2 in Brca1-associated breast cancers, Br J Cancer, 83, 1318, 10.1054/bjoc.2000.1438 Manie, 2009, High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors, Cancer Res, 69, 663, 10.1158/0008-5472.CAN-08-1560 Turner, 2006, Basal-like breast cancer and the BRCA1 phenotype, Oncogene, 25, 5846, 10.1038/sj.onc.1209876 Bane, 2009, Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors, Breast Cancer Res Treat, 117, 183, 10.1007/s10549-008-0087-1 Banneau, 2010, Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations, Breast Cancer Res, 12, R63, 10.1186/bcr2626 Farmer, 2005, Identification of molecular apocrine breast tumours by microarray analysis, Oncogene, 24, 4660, 10.1038/sj.onc.1208561 Bougeard, 2015, Revisiting Li-Fraumeni syndrome from TP53 mutation carriers, J Clin Oncol, 33, 2345, 10.1200/JCO.2014.59.5728 Rath, 2013, Prevalence of germline TP53 mutations in HER2+ breast cancer patients, Breast Cancer Res Treat, 139, 193, 10.1007/s10549-012-2375-z Hoang, 2017, Hereditary breast and ovarian cancer syndrome: moving beyond BRCA1 and BRCA2, Adv Anat Pathol, 25, 85, 10.1097/PAP.0000000000000177 Corso, 2018, Clinical implication of E-cadherin deficiency in lobular breast cancer, Breast Cancer Res Treat, 173, 751, 10.1007/s10549-018-5051-0 Corso, 2016, CDH1 germline mutations and hereditary lobular breast cancer, Fam Cancer, 15, 215, 10.1007/s10689-016-9869-5 Renault, 2018, Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers, Breast Cancer Res, 20, 28, 10.1186/s13058-018-0951-9